15-Year watch begins for new cancer cell therapy
NCT ID NCT06985576
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 18 people who previously received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will track side effects and how long the modified cells last in the body for up to 15 years. The goal is to ensure the treatment remains safe over the long term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GF-CART01 (a type of CAR T-cell therapy targeting CD20 and CD19 proteins on cancer cells)
What this could lead to
If successful, this study will confirm the long-term safety and durability of GF-CART01, supporting its use as a treatment for certain blood cancers.
What could go wrong
This is a small, observational follow-up study with only 18 participants, so results may not apply to everyone. It does not test new treatments, only monitors past ones.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan